Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that
is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in …

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …

CXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to
regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in …

Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …

Introduction: Despite unprecedented advances in the treatment of multiple myeloma (MM),
almost all patients develop a disease that is resistant to the five most commonly used and …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death attributed
to high frequency of metastasis and multiple drug resistance. We aim to examine the …

Patient mortality rates have remained stubbornly high for the past decades in small cell lung
cancer (SCLC) because of having no standard targeted therapies with confirmed …

Development of targeted therapies in recent years revealed several nonchemotherapeutic
options for patients. Chief among targeted therapies is small molecule kinase inhibitors …

Thymus vulgaris and Arctium lappa have been used as a folk remedy in the Iraqi Kurdistan
region to deal with different health problems. The aim of the current study is to investigate …